2718. Prevalence of Infections Following Anti-CD30 Targeted Chimeric Antigen Receptor T-cell Therapy for Relapsed and Refractory Lymphoma

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed or refractory hematologic malignancies. Clinical trials have demonstrated anti-CD30 CAR T-cell efficacy in patients with CD30+ malignancies such as Hodgkin lymphoma, but little is known about post...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohnasky, Michael C, Huggins, Jonathan, Messina, Julia A, Saha, Manish K, Saullo, Jennifer, Smith, Melody, Stromberg, Joseph, Walsh, Megan, Andermann, Tessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677856/
http://dx.doi.org/10.1093/ofid/ofad500.2329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677856/
http://dx.doi.org/10.1093/ofid/ofad500.2329

Ejemplares similares